Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

135.84 +0.29 (+0.21%)
Official Closing Price Updated: 7:00 PM EDT, Aug 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
News headline image
KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck KANDLELIT Trials Spark Hope For Hard-To-Treat Cancers ↗
Merck shared safety and efficacy results of MK-1084; either as monotherapy or in combinations, it demonstrated a manageable safety profile. 
Via Benzinga
News headline image
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure ↗
There's a long history of anti-PD-1 and anti-VEGF drugs working to slow progression, but not improve overall survival. 
Via Investor's Business Daily
News headline image
How Do Investors Really Feel About Merck & Co? ↗
 
Via Benzinga
News headline image
Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair Wrap Up Successfully
From HKTDC
Via ACN Newswire
News headline image
Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial
From Merck & Co., Inc.
Via Business Wire
News headline image
2 Cash-Producing Stocks for Long-Term Investors and 1 to Steer Clear Of
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
Merck, Daiichi Sankyo Pull FDA Application For Lung Cancer Therapy: Retail Terms It A ‘Huge Flop’ ↗
The decision is based on results from a late-stage trial in which the drug failed to prolong patients' lives, the companies stated. 
Via Stocktwits
News headline image
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% ↗
Keros ends PAH development of cibotercept after Phase 2 safety issues, including pericardial effusions, and plans to cut 45% of workforce amid review. 
Via Benzinga
News headline image
Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn
From Daiichi Sankyo
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Merck Announces Third-Quarter 2025 Dividend
From Merck & Co., Inc.
Via Business Wire
News headline image
MERCK & CO. INC. (NYSE:MRK) - A Reliable Dividend Stock with Strong Fundamentals ↗
MERCK & CO. (NYSE:MRK) offers a strong 4.2% dividend yield, consistent growth, and solid financial health, making it a top pick for dividend investors. 
Via Chartmill
News headline image
"If Walmart Is Under Pressure to Raise Prices, It's Going to Have Broader Effects on the Economy." ↗
Via The Motley Fool
Topics Earnings Economy World Trade
News headline image
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics ↗
The companies are duking it out for the best treatment for head-and-neck cancer. One clearly has the edge. 
Via Investor's Business Daily
News headline image
3 Dow Jones Stocks on Our Watchlist
The Dow Jones (^DJI) includes some of the most reliable stocks in the market, and while not all are equal, a few continue to shine. These companies are leveraging their strengths to maintain leadership... 
Via StockStory
Topics Stocks
News headline image
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗
 
Via Benzinga
News headline image
Moderna Stock Looks Ripe for a Short Squeeze
Moderna stock has made single-digit gains in the last month, and high short interest suggests that any bullish news could cause a short squeeze 
Via MarketBeat
Topics Government
News headline image
Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference
From Merck & Co., Inc.
Via Business Wire
News headline image
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 ↗
Via The Motley Fool
Topics Economy Law Enforcement
News headline image
Spotlight on Merck & Co: Analyzing the Surge in Options Activity ↗
 
Via Benzinga
News headline image
MERCK & CO. INC. (NYSE:MRK) - A Strong Value Candidate in Pharmaceuticals ↗
MERCK & CO. (NYSE:MRK) offers strong value with a low P/E ratio, high profitability, and a reliable dividend. A solid pick for value investors in the pharmaceutical sector. 
Via Chartmill
News headline image
IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
From Daiichi Sankyo
Via Business Wire
News headline image
Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension
From Merck & Co., Inc.
Via Business Wire
News headline image
Decoding Merck & Co's Options Activity: What's the Big Picture? ↗
 
Via Benzinga
News headline image
Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda ↗
Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors. 
Via Benzinga
News headline image
Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo ↗
Immutep's efti combo with Keytruda and chemo shows a 60.8% response rate in lung cancer trial, with strong efficacy across PD-L1 expression levels. 
Via Benzinga
News headline image
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025 ↗
For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity. 
Via Benzinga
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.